Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sipuleucel-T in Newly Diagnosed Prostate Cancer on Active Surveillance
NCT03686683Phase 3Completed
- Sponsor
- Dendreon
- Start
- Oct 2018
- Primary completion
- Mar 2023
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 3 trial of sipuleucel-T in prostate cancer (PCa), sponsored by Dendreon. Started Oct 2018; status: completed.
02
Drugs
sipuleucel-T
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03686683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03686683.